CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 38 enrolled
Drug / intervention
mepolizumabbiological
Likely dose
mepolizumab 750mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00802438
NCT00802438N/ACompleted
CompareCT.gov

Eosinophilic Airway Inflammation: Relationship to Remodeling and Modulation by Mepolizumab

University of Wisconsin, Madison·interventional·Posted Dec 5, 2008·Updated Apr 10, 2019

In Brief

A clinical study evaluating mepolizumab for Asthma. Completed, enrolled 38 participants across 1 site.

Detailed Summary

A drug (mepolizumab) that reduces allergic inflammation will affect the function of allergy cells called eosinophils which are produced by the body in response to allergen exposure.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 5, 2008
Enrollment StartJun 1, 2008
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 17.6 years ago

Interventions

mepolizumabbiological

up to three monthly doses of 750mg i.v. mepolizumab